Sunday, November 1, 2015
Pca is a heterogeneous diesease and hence would probably respond well with polymerase inhibition. The New England Journal of Medicine posted a report on 29 October 2015 on the successful trials of Olapalip. PCa patients who had not responded to standard treatments and who had defects in their DNA repair genes achieved a high degree of success.
Olaparib is produced by AstraZeneca and recently approved by the FDA.
Visit site below for full report:
Good things are a-coming.
Posted by Allen Lai at 8:24 AM